| Name | Ursodeoxycholic Acid (UDCA) |
|---|---|
| CAS | 128-13-2 |
| Molecular formula | C24H40O4 |
| Molecular weight | 392.57 |
| EP assay | 99.0–101.0% (anhydrous) |
| USP assay | 98.0–102.0% (anhydrous) |
| CDCA (Impurity A) | ≤ 0.10% (EP) |
| LCA (Impurity B) | ≤ 0.15% (EP) |
| Residual solvents | ICH Q3C |
| Packaging | 25 KG / DRUM, PE-lined |
| GMP status | Supplier-stated; certificate to be verified |
Ursodeoxycholic acid (UDCA, CAS 128-13-2) is a secondary bile acid supplied as a pharmaceutical API against pharmacopoeial monographs or an in-house specification. Its quality standards are defined by the assay range on the anhydrous basis, the limits on two monographed impurities — chenodeoxycholic acid and lithocholic acid — and the solvent and elemental impurity frameworks the batch is released against.
UDCA is a white to off-white crystalline powder with the molecular formula C24H40O4 and a molecular weight of 392.57. It is released against one of the pharmacopoeial monographs — most commonly the European Pharmacopoeia (monograph 1275) or the United States Pharmacopeia — or against a customer-specific in-house specification written to the same test set.
| Parameter | Specification | Reference |
|---|---|---|
| Identity | IR and specific rotation confirmatory | EP / USP monograph |
| Assay (anhydrous basis) | 99.0–101.0% (EP) · 98.0–102.0% (USP) | EP 1275 / USP |
| CDCA — Impurity A | ≤ 0.10% | EP 1275 |
| LCA — Impurity B | ≤ 0.15% | EP 1275 |
| Any other individual impurity | ≤ 0.10% | EP 1275 |
| Total impurities | ≤ 0.5% | EP 1275 |
| Specific rotation | +58.0° to +62.0° (anhydrous) | EP / USP monograph |
| Loss on drying | ≤ 1.0% | EP / USP monograph |
| Heavy metals | ≤ 20 ppm | EP Method A / USP Method II |
| Residual solvents | ICH Q3C; ethanol ≤ 5,000 ppm | ICH Q3C / USP <467> |
| Microbial limits | TAMC ≤ 1000 CFU/g; TYMC ≤ 100 CFU/g | EP 5.1.4 / USP <61><62> |
These figures are the monographed limits. A supplier's certificate of analysis reports the actual measured result, which normally sits inside the range rather than at the boundary — and the batch documentation, not a general specification sheet, is what confirms which standard a specific lot was released against.
The standard a buyer should specify depends on the destination market and on what the finished product is registered against. There are three practical answers, and they are not interchangeable.
The European Pharmacopoeia and the United States Pharmacopeia are the two most widely referenced for ursodeoxycholic acid. The EP monograph is the reference most European buyers quote against; the USP monograph is common in the United States and in markets that follow USP practice. The British Pharmacopoeia, Japanese Pharmacopoeia and Indian Pharmacopoeia are also in use, and each carries its own assay range and impurity limits.
An in-house specification is written by the manufacturer or agreed between buyer and supplier. It normally follows the same test set as a monograph but may set tighter or looser individual limits, add a particle-size requirement, or fix a different assay basis. Where a material is released against an in-house specification, the specification document itself — not the monograph — is what the certificate of analysis should be read against.
State the monograph (or in-house specification), the assay basis, the destination market and the documentation the buyer's registration file will require. Those four items determine the release criteria, the test methods and the paperwork, and leaving any of them implicit is a common cause of a quotation that cannot be compared with the next one. The USP vs EP comparison sets the two monographs out side by side parameter by parameter.
Ursodeoxycholic acid is assayed on the anhydrous basis, and the basis is the single most common source of confusion in a UDCA specification. A lot reported on an as-is basis will read lower than the same lot reported on the anhydrous basis, because the as-is figure includes the water the sample carries.
The EP monograph specifies 99.0–101.0% on the anhydrous basis; the USP monograph specifies 98.0–102.0%. The EP range is the tighter of the two, and it is one of the reasons the two grades are not interchangeable in a registration file. Where a supplier quotes an assay figure without stating the basis, the figure cannot be compared against a monograph limit — the basis has to be established first.
The assay method also differs between the two monographs. The EP monograph uses potentiometric titration; the USP monograph uses HPLC. A buyer comparing certificates from two suppliers should confirm they were tested by the same method, because a result generated by a different method is not a like-for-like comparison even when both fall inside the stated range.
Two impurities are monographed for ursodeoxycholic acid, and both are bile acids rather than unrelated contaminants. Chenodeoxycholic acid (CDCA) is Impurity A, limited to not more than 0.10% under the EP monograph; lithocholic acid (LCA) is Impurity B, limited to not more than 0.15%. Any other individual impurity is limited to not more than 0.10%, and total impurities to not more than 0.5%.
These limits are process controls as much as they are analytical limits. Ursodeoxycholic acid is produced from chenodeoxycholic acid, and CDCA is therefore both the starting material for the conversion and the principal residual impurity to be controlled. The Chinese bile acid chain runs from poultry bile through bile paste to CDCA and then to UDCA, so the profile of the starting material directly shapes the impurity profile of the finished API — a well-controlled CDCA step is what makes the 0.10% limit achievable in routine production rather than only in a development batch.
Lithocholic acid is a downstream consideration of the same chemistry: it is a more hydrophobic bile acid, and keeping it below the monograph limit is a function of how completely the reduction step is controlled and how the purification is run. A certificate showing both impurities close to their limits is worth a question about process consistency; a certificate showing them well inside the limits, batch after batch, is the more informative signal.
Residual solvents in ursodeoxycholic acid are controlled under ICH Q3C, which classifies solvents by their toxicological risk and sets a permitted daily exposure for each. The EP monograph specifies a limit for ethanol of not more than 5,000 ppm; other solvents are controlled by the Q3C classification and by the USP <467> framework in the United States.
Elemental impurities are handled as a risk assessment rather than as a single numeric limit. ICH Q3D requires the manufacturer to assess the elemental impurity risk of the process, identify the elements that could be introduced by equipment, reagents and raw materials, and set controls accordingly. A buyer should expect the assessment itself, not only a heavy-metals figure — a heavy-metals test reported against the traditional ≤ 20 ppm limit answers a different question from a Q3D risk assessment.
Neither framework has a single answer that applies to every supplier. What the buyer can reasonably ask for is the vendor's Q3C solvent statement and its Q3D elemental impurity risk assessment for the process in question, and confirmation that the certificate of analysis was generated under the same controls.
The test set below is the one a UDCA certificate of analysis is normally built from. The method matters as much as the result: two certificates can both report a compliant assay while having been generated by different methods and therefore not being directly comparable.
| Test | Method | Reference |
|---|---|---|
| Assay | Potentiometric titration (EP) · HPLC (USP) | EP 1275 / USP monograph |
| Related substances | HPLC with UV detection | EP 1275 / USP monograph |
| Identity | Infrared absorption; specific rotation | EP 1275 / USP monograph |
| Loss on drying | Gravimetric | EP / USP monograph |
| Heavy metals | EP Method A · USP Method II | EP / USP monograph |
| Residual solvents | Gas chromatography | ICH Q3C / USP <467> |
| Microbial limits | Microbial enumeration | EP 5.1.4 / USP <61><62> |
The documents that travel with a UDCA batch are the certificate of analysis, the material safety data sheet and the TSE/BSE statement, with a certificate of origin added where the destination market asks for one. The certificate of analysis is issued per batch and references the batch number, the specification the lot was released against, the test methods used, the measured results and a dated signature from quality control.
A TSE/BSE statement is part of the standard documentation package for ursodeoxycholic acid. Because the material is produced from poultry bile by way of chenodeoxycholic acid, the statement addresses the manufacturing process and the poultry-derived starting material. The current version should be confirmed with the supplier and requested together with the batch documentation.
Ursodeoxycholic acid is a solid material and is commonly stored in a sealed, light-protected container at ambient temperature, following the handling practice used across the Chinese API export trade. The storage condition and the re-test period assigned to a specific lot are set by the manufacturer and recorded in the batch documentation, and they should be read from there rather than assumed from a general specification sheet. Product packaging is 25 KG per drum with a PE liner.
Send the monograph or in-house specification, the assay basis, the destination market and your annual volume. We reply with the specification sheet, a specimen certificate of analysis and the current documentation package.